The pharmaceutical company at the center of the EpiPen price-gouging controversy has decided to lower the cost of its medication for some patients.
Mylan, which had hiked the price of the medication by more than 400 percent, announced plans to cover up to $300 — or roughly 50 percent — of the cost of a pack of two EpiPens for patients who were paying the full amount.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Already a print subscriber? Click here to login/register your account
